WO2000043333A2 - Method for the combinatorial search for reactions for producing useful products - Google Patents
Method for the combinatorial search for reactions for producing useful products Download PDFInfo
- Publication number
- WO2000043333A2 WO2000043333A2 PCT/EP2000/000462 EP0000462W WO0043333A2 WO 2000043333 A2 WO2000043333 A2 WO 2000043333A2 EP 0000462 W EP0000462 W EP 0000462W WO 0043333 A2 WO0043333 A2 WO 0043333A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- products
- starting materials
- reaction
- chemical
- properties
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 164
- 238000006243 chemical reaction Methods 0.000 title claims abstract description 96
- 239000007858 starting material Substances 0.000 claims abstract description 101
- 150000001875 compounds Chemical class 0.000 claims abstract description 71
- 239000000126 substance Substances 0.000 claims abstract description 66
- 238000012360 testing method Methods 0.000 claims abstract description 46
- 238000006452 multicomponent reaction Methods 0.000 claims abstract description 44
- 238000004519 manufacturing process Methods 0.000 claims abstract description 20
- 239000000047 product Substances 0.000 claims description 108
- 230000008569 process Effects 0.000 claims description 31
- 238000004422 calculation algorithm Methods 0.000 claims description 22
- 239000007795 chemical reaction product Substances 0.000 claims description 18
- 230000004071 biological effect Effects 0.000 claims description 15
- 125000000524 functional group Chemical group 0.000 claims description 12
- 230000000875 corresponding effect Effects 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 11
- 238000012986 modification Methods 0.000 claims description 11
- 230000004048 modification Effects 0.000 claims description 11
- 238000005457 optimization Methods 0.000 claims description 11
- -1 cobalt chloride Chemical class 0.000 claims description 10
- 238000011156 evaluation Methods 0.000 claims description 10
- 239000003054 catalyst Substances 0.000 claims description 9
- 238000013528 artificial neural network Methods 0.000 claims description 8
- 230000002068 genetic effect Effects 0.000 claims description 8
- 230000000144 pharmacologic effect Effects 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 150000001299 aldehydes Chemical class 0.000 claims description 5
- 238000004458 analytical method Methods 0.000 claims description 5
- 210000000056 organ Anatomy 0.000 claims description 5
- 125000006239 protecting group Chemical group 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 150000001735 carboxylic acids Chemical class 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 238000005984 hydrogenation reaction Methods 0.000 claims description 4
- 238000012567 pattern recognition method Methods 0.000 claims description 4
- 239000000376 reactant Substances 0.000 claims description 4
- 239000000741 silica gel Substances 0.000 claims description 4
- 229910002027 silica gel Inorganic materials 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 238000010998 test method Methods 0.000 claims description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 238000004587 chromatography analysis Methods 0.000 claims description 3
- 230000001419 dependent effect Effects 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 3
- 238000012804 iterative process Methods 0.000 claims description 3
- 150000002576 ketones Chemical class 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 2
- 102000004195 Isomerases Human genes 0.000 claims description 2
- 108090000769 Isomerases Proteins 0.000 claims description 2
- 239000002841 Lewis acid Substances 0.000 claims description 2
- 108090000364 Ligases Proteins 0.000 claims description 2
- 102000003960 Ligases Human genes 0.000 claims description 2
- 102000004882 Lipase Human genes 0.000 claims description 2
- 108090001060 Lipase Proteins 0.000 claims description 2
- 239000004367 Lipase Substances 0.000 claims description 2
- 102000004316 Oxidoreductases Human genes 0.000 claims description 2
- 108090000854 Oxidoreductases Proteins 0.000 claims description 2
- 102000035195 Peptidases Human genes 0.000 claims description 2
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 150000001336 alkenes Chemical class 0.000 claims description 2
- 150000004716 alpha keto acids Chemical class 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 239000002585 base Substances 0.000 claims description 2
- 229940098773 bovine serum albumin Drugs 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 2
- 239000013592 cell lysate Substances 0.000 claims description 2
- 238000012512 characterization method Methods 0.000 claims description 2
- 238000007385 chemical modification Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229910052804 chromium Inorganic materials 0.000 claims description 2
- 239000011651 chromium Substances 0.000 claims description 2
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 claims description 2
- 150000004696 coordination complex Chemical class 0.000 claims description 2
- 230000002596 correlated effect Effects 0.000 claims description 2
- LSXWFXONGKSEMY-UHFFFAOYSA-N di-tert-butyl peroxide Chemical compound CC(C)(C)OOC(C)(C)C LSXWFXONGKSEMY-UHFFFAOYSA-N 0.000 claims description 2
- 125000003700 epoxy group Chemical group 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 239000003456 ion exchange resin Substances 0.000 claims description 2
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 2
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 claims description 2
- VRWKTAYJTKRVCU-UHFFFAOYSA-N iron(6+);hexacyanide Chemical compound [Fe+6].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] VRWKTAYJTKRVCU-UHFFFAOYSA-N 0.000 claims description 2
- 150000002527 isonitriles Chemical class 0.000 claims description 2
- 150000007517 lewis acids Chemical class 0.000 claims description 2
- 235000019421 lipase Nutrition 0.000 claims description 2
- 238000005259 measurement Methods 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 239000002808 molecular sieve Substances 0.000 claims description 2
- 150000002825 nitriles Chemical class 0.000 claims description 2
- 238000002414 normal-phase solid-phase extraction Methods 0.000 claims description 2
- HGASFNYMVGEKTF-UHFFFAOYSA-N octan-1-ol;hydrate Chemical compound O.CCCCCCCCO HGASFNYMVGEKTF-UHFFFAOYSA-N 0.000 claims description 2
- 150000002905 orthoesters Chemical class 0.000 claims description 2
- 239000007800 oxidant agent Substances 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 claims description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 claims description 2
- 229910003446 platinum oxide Inorganic materials 0.000 claims description 2
- 235000019833 protease Nutrition 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 239000011347 resin Substances 0.000 claims description 2
- 229920005989 resin Polymers 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 2
- 239000007790 solid phase Substances 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- 150000003566 thiocarboxylic acids Chemical class 0.000 claims description 2
- AHZJKOKFZJYCLG-UHFFFAOYSA-K trifluoromethanesulfonate;ytterbium(3+) Chemical compound [Yb+3].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F AHZJKOKFZJYCLG-UHFFFAOYSA-K 0.000 claims description 2
- 239000011592 zinc chloride Substances 0.000 claims description 2
- 235000005074 zinc chloride Nutrition 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 2
- 238000009826 distribution Methods 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 238000009419 refurbishment Methods 0.000 claims 1
- 229930001119 polyketide Natural products 0.000 description 18
- 125000000830 polyketide group Chemical group 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 125000001424 substituent group Chemical group 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000009897 systematic effect Effects 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 108010030975 Polyketide Synthases Proteins 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 150000003881 polyketide derivatives Chemical class 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000005556 structure-activity relationship Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000000507 anthelmentic effect Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 238000007363 ring formation reaction Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- HSJKGGMUJITCBW-UHFFFAOYSA-N 3-hydroxybutanal Chemical compound CC(O)CC=O HSJKGGMUJITCBW-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000006757 chemical reactions by type Methods 0.000 description 2
- 238000013098 chemical test method Methods 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000011814 protection agent Substances 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 150000007970 thio esters Chemical class 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- SMQBKIJQCAFMBA-UHFFFAOYSA-N 2-(4,6-dioxocyclohex-2-en-1-yl)butanoic acid Chemical compound O=C1C(C=CC(C1)=O)C(C(=O)O)CC SMQBKIJQCAFMBA-UHFFFAOYSA-N 0.000 description 1
- OXTNCQMOKLOUAM-UHFFFAOYSA-N 3-Oxoglutaric acid Chemical compound OC(=O)CC(=O)CC(O)=O OXTNCQMOKLOUAM-UHFFFAOYSA-N 0.000 description 1
- OAKURXIZZOAYBC-UHFFFAOYSA-N 3-oxopropanoic acid Chemical compound OC(=O)CC=O OAKURXIZZOAYBC-UHFFFAOYSA-N 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 238000003512 Claisen condensation reaction Methods 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- GKKZMYDNDDMXSE-UHFFFAOYSA-N Ethyl 3-oxo-3-phenylpropanoate Chemical compound CCOC(=O)CC(=O)C1=CC=CC=C1 GKKZMYDNDDMXSE-UHFFFAOYSA-N 0.000 description 1
- 102000015303 Fatty Acid Synthases Human genes 0.000 description 1
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 1
- 229930191564 Monensin Natural products 0.000 description 1
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 1
- 102000006833 Multifunctional Enzymes Human genes 0.000 description 1
- 108010047290 Multifunctional Enzymes Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000005575 aldol reaction Methods 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 150000004718 beta keto acids Chemical class 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 125000001721 carboxyacetyl group Chemical group 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- 238000006258 combinatorial reaction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- 150000003883 epothilone derivatives Chemical class 0.000 description 1
- OYQVQWIASIXXRT-UHFFFAOYSA-N ethyl 2,4-dioxopentanoate Chemical compound CCOC(=O)C(=O)CC(C)=O OYQVQWIASIXXRT-UHFFFAOYSA-N 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 229960005358 monensin Drugs 0.000 description 1
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 229940072172 tetracycline antibiotic Drugs 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000010490 three component reaction Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003245 working effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/08—Liquid phase synthesis, i.e. wherein all library building blocks are in liquid phase or in solution during library creation; Particular methods of cleavage from the liquid support
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
Definitions
- the present invention relates to the discovery and production of chemical compounds with desired and useful physical, chemical and / or biological properties by means of an iterative process based on multicomponent reactions.
- the compounds according to the invention can be used as medicaments, veterinary products, vaccines, cosmetics, crop protection agents etc. or as additives to these or as ligands, catalysts, catalytic cofactors, detector molecules, polymers, peptides and adhesives.
- the low diversity also has advantages: since the compounds are always manufactured and tested as chemically related families, one obtains limited structure-activity relationships (SAB). These SAB enable the exclusion of frequently occurring errors in the biological testing, such as false positive or false negative signals, which can occur due to device errors, contamination in the test samples, etc. Such a SAB can also provide information on a possible optimization of the chemical compounds with regard to their biological and other properties.
- SAB structure-activity relationships
- Random substance libraries usually do not show the disadvantages of low diversity described above (JPDevlin, The Discovery of Bioactive Substances - High Throughput Screening, Marcel Dekkert, 1998).
- the broad testing of these substance libraries for various biological effects is therefore a standard way of finding biologically active compounds.
- the disadvantage of this process is that the compounds found in this way can often not be prepared with a simple, efficient and rapid synthesis.
- the development of a combinatorial synthesis as an access to these compounds for the optimization of the substance properties is time-consuming and expensive.
- Another disadvantage of these random substance libraries in their biological testing is that they are not systematically structured, which does not allow the exclusion of false positive or false negative test results due to SAB.
- Another object of the present invention is a new access to new classes of substances such as polyketides, in just one or a few steps.
- a method for the quick and efficient detection and production of biologically active compounds is provided, which solves the tasks described above, in particular the tasks (a-h), and thus eliminates the shortcomings of known processes.
- the process includes the following steps:
- MCRs multicomponent reactions
- a set of M different starting materials suitable for multicomponent reactions is therefore first selected. Then all MCRs which are possible with these starting materials are carried out with these starting materials, preferably at least 3 starting materials and at most all starting materials being reacted with one another. At 5 Educts are thus possible, for example, reactions of all combinations of three and all combinations of four and a reaction of the combination of five.
- This product or product can then be compared with the next best product or products, if necessary, in order to draw conclusions about possible factors which are relevant for the effect of the best product or products.
- the product of a 5-component reaction has good properties, it is compared with the products of the 4-component reactions possible with these components and also with products which have been prepared by 6-component reactions in which, in addition to the 5 in the 5- Use component reaction another educt is used. If, for example, the product of the 4-component reaction has similarly good properties as the product of the 5-component reaction, it can be concluded that the 5th component does not contribute to the properties of the product and, for example, only acts as a catalyst or not at all in the reaction is involved.
- one or more products are selected.
- the next step is to determine the starting materials that have led to the selected product that has the best properties. If, in the example given above, the product produced from 5 starting materials has the best properties, these 5 starting materials are used in the further steps of the process.
- At least one of the starting materials e.g. an amine component is then varied or modified in the sense that e.g. at least one substituent is exchanged and / or at least one (further) substituent is introduced.
- at least one substituent is exchanged and / or at least one (further) substituent is introduced.
- 2, 3 or all of the starting materials can also be chemically varied or modified.
- the varied or modified starting materials are then unset within the same MCR as in the previous ones Stages of the process has led to the optimal product. If, for example, 2 starting materials are modified in the above example in such a way that a further variant of each of these two starting materials is present, but the other three starting materials are used unmodified, three new reactions of the same MCR type are possible, since in one reaction three original starting materials and two new starting materials and in the other two reactions four original starting materials and one modified starting material each can be used.
- the product or products with the best properties are then selected again and, if necessary, determined on the basis of the variations or modifications, which is the reason for the improvement in properties that may have occurred: e.g. found that the enlargement of a substituent on an amine component leads to an improvement in the properties, one will select starting materials when the steps are repeated, in which at least one substituent on the amine component is further increased.
- the substituents on the selected framework are changed until a product with an optimal effect has been found.
- An advantage of the method disclosed here compared to conventional methods for binding active substances is the rapid and efficient finding of chemical compounds which fulfill a desired objective function.
- the target function can be, for example, a specific biological activity and / or a spectrum of other desired pharmacological and physico-chemical properties and is varied depending on the molecule sought, etc. These are preferably therapeutic properties.
- a further advantage of the method disclosed here is that neither knowledge of the chemical structure of the compounds to be produced or produced, nor knowledge of the chemical reactions taking place in the experiments, is necessary to find such compounds. It is therefore not necessary to create complex structure-activity relationships.
- a further advantage of the method disclosed here is that the desired product can be produced in a multicomponent reaction, be it via an already known chemical reaction or through a new chemical reaction found in the method according to the invention, and that the product is thus accessible through very simple chemical process steps even if the connections are structurally very complicated.
- Another advantage of the process disclosed here is that the combinatorics of the different starting materials result in a large number of new and different chemical basic structures, not only the substituents of these basic structures, but also the basic structures themselves can be varied and checked for their suitability for finding novel compounds with excellent properties.
- Another advantage is that the efficiency of the method according to the invention for the discovery and production of biologically active chemical compounds can be measured in a simple manner.
- the diversity i.e. the information content of chemical reactions, chemical compounds or substance libraries can be adapted to the individual phases of the discovery, optimization and production of chemical compounds with the desired properties or can correspond to them, especially since the advantages of combinatorial substance libraries are combined with those of the random libraries.
- a method is thus disclosed which provides fast and efficient access to new compounds with pharmacologically outstanding properties through the iterative selection of the starting materials, the production of selected products by means of multicomponent reactions and their biological, pharmacological and / or physico-chemical testing, especially theirs Testing for their therapeutic potential, made possible in several cycles.
- the process can be used, for example, to produce any product with desired properties, such as medicinal products. elements, veterinary products, vaccines, cosmetics, crop protection agents etc. or additives to these or ligands, catalysts, catalytic cofactors, detector molecules, polymers, peptides and adhesives.
- the invention relates to both the method and the products found using this method.
- a number M of different chemical starting materials is selected that contain functional groups that are common in organic chemistry and suitable for multicomponent reactions (MRCs) such as Passerini or Ugi MCRs (J.March, Advanced Organic Chemistry , Wiley-Interscience, New York, 1984)
- Some of the functional groups can be provided with protective groups customary in organic chemistry (T.W. Greene, protective groups in organic synthesis, Wiley-Interscience, New York, 1981).
- Educts which are known to be good educts for multicomponent reactions, such as alpha-haloketones, esters, carboxylic acids, thiocarboxylic acids, aldehydes, amines, ketones, isonitriles, nitriles, alpha-keto acids, alpha-keto esters, and their derivatives and al - Pha-beta unsaturated variants, as well as combinations thereof, particular mono-, di-, tri-, tetra-, penta- or hexacarbonyl variants of the above-mentioned functional groups being particularly preferred.
- these M educts are preferably encoded in a form accessible to an algorithm, with the selected educts being assigned randomly or systematically binary, decimal or alphanumeric encodings.
- a characteristic basic coding such as "A” is preferably assigned to a starting material type of a certain chemical class, such as aldehydes, with particular preference being given to different starting materials which fall into this class, like various special aldehydes, an additional coding such as the numbers "1, 2, 3 " is assigned randomly, so that there is an alphanumeric total coding AI for benzaldehyde and A2 for acetaldehyde, or B1 for A ilin and B2 for methylamine.
- Chemical classes thus designate e.g. Aldehydes, ames, carboxylic acids, in particular they denote component groups of MCRs.
- N different codings are obtained for M different starting materials.
- the amount N is intended to mean the amount of the (different) educt classes or chemical classes, an educt according to the invention being able to be assigned to various such classes and coded accordingly, e.g. Beta-ketopropionic acid can be assigned to the class of ketones, carboxylic acids or beta-keto acids.
- a coding is particularly preferred in which each educt is coded in only one class at a time.
- the product space i. the type and quantity of the products to be expected to be obtained are selected or specified at least to a certain extent.
- the process according to the invention is preferably M 40, more preferred is M ⁇ 30, even more preferred is M ⁇ 20 and most preferred is M ⁇ 12. 2)
- the starting materials are reacted simultaneously or sequentially as part of an - also unknown - MCR.
- Each starting material is reacted with any other starting material or preferably any possible combination of 2 to 1 ml of other starting materials, which are selected in the first process step.
- An advantage of the process according to the invention is that knowledge of the possible reactions which these starting materials can undergo is not necessary.
- the optionally selected starting materials in one or more solvents such as methanol, tetrahydrofuran, dioxane, dimethyl sulfoxide, water or mixtures thereof, possibly with the exclusion of air or in a nitrogen, oxygen, hydrogen or argon atmosphere in a temperature range between -60 ° C.
- auxiliaries or catalysts such as Lewis acids such as boron trifluoride etherate, zinc chloride, ytterbium triflate, iron chloride, other acids such as hydrochloric acid, para-toluenesulfonic acid, acetic acid or bases such as potassium carbonate, triethylamine, cesium carbonate, or dehydrated water IS pulling agents such as molecular sieves or orthoesters are used.
- Each of these experiments can be spatially separated and in a comprehensible manner, e.g. in different reaction vessels, and in particular the assignment of the different combinations with their coding to the positions of the reaction vessels are stored in a form accessible to an algorithm in the computer.
- reaction products obtained can be further chemically modified, worked up or prepared for step (3) in a suitable manner in a subsequent step.
- Such a chemical modification can, for example, remove the chemical protective groups, for example by luoroacetic acid, or the hydrogenation of the products with the aid of hydrogen, optionally with the addition of a hydrogenation catalyst such as, for example, palladium on carbon, platinum oxide, palladium acetate, or by the oxidation of the products with oxygen or another oxidizing agent such as, for example, bromine, hydrogen peroxide, tert-butyl peroxide or a suitable metal salt such as cobalt chloride, or a suitable metal complex such as iron hexacyanoferrate or chromium tetraphenyl porphyrinate or by irradiation with light of wavelength 200-600 nm.
- the reaction products can be treated with one or more enzymes, such as oxidoreductases, ligases, peptidases, lipases or isomerases.
- the products can be worked up in a manner known per se, such as by chromatography, e.g. via silica gel or RP-18 silica gel, or solid phase extraction or the removal of unreacted starting materials by binding to a suitable solid support such as e.g. Ion exchange resins or chemically modified solid phase resins take place, or the expected products can be purified by selective binding to such a solid support with subsequent washing and detachment from this support.
- test solution can be prepared.
- reaction conditions, modifications, workings or preparations for the test used can also be in a form suitable for an algorithm, eg in binary, decimal or alphanumeric form.
- a reaction product can thus be coded, for example, either as a combination of the coding of the starting materials used or, preferably, as a combination of the coding of the starting materials used and the coding for the reaction conditions used, modifications, work-ups or preparations for testing, both of which are used in a particularly preferred manner Educts, the reaction conditions, modifications, work-ups or preparations for testing as well as the reaction vessels are encoded.
- Such a coding is to be referred to hereinafter simply as the genome of the reaction product.
- test solutions of the products from the second process step are, for example, in a biological and / or pharmacological and / or physico-chemical test for their biological activity, effectiveness, side effects or selectivity and / or another test procedure the physico-chemical properties of these products examined.
- the dependence of the measurement results on the concentration of the starting materials used in process step two is preferably examined and ascertained.
- a concentration range from 0.5 to 0.000001 mol / 1, particularly preferably a concentration range from 100 to 0.01 mol / 1, is examined.
- the test for determining the biological or pharmacological activity, effectiveness, side effects or selectivity is preferably carried out with isolated proteins, receptors, enzymes or mixtures thereof, cells, cell lysates, complex cell systems, with organs or parts thereof or with several organs or also with whole organs Organisms or membranes and optionally carried out using auxiliary substances, substrates or detection aids necessary for the test.
- test methods for the physico-chemical properties of the products can, for example, measure the lipology by the octanol-water partition coefficient, the solubility in water, the non-specific protein binding to eg bovine serum albumin, the binding to the pro include human serum plasma or chemical stability in cancer buffer.
- test results obtained are preferably compared with the genomes of the reaction products, preferably in a form accessible to the algorithm, e.g. correlated in a computer data file or a computer database.
- the list of genomes and the test results assigned to them contains all the information necessary for further optimization.
- the method according to the invention can implicitly use a statistical analysis of the reactions and work steps carried out, the systematics used in the selection of the educts M making it possible to dispense with the precise and explicit knowledge of the chemical reactions and structures of the resulting compounds.
- a reaction which is per se desirable and known does not take place, but another reaction which has not hitherto been known provides a new chemical compound which has desirable properties, e.g. oral bioavailability.
- the corresponding genome of this reaction product and the associated test results thus also implicitly contain the process, as well as the yield and structure of the chemical compound from this new multicomponent reaction. This makes it possible to use this reaction with the algorithm according to the invention even without its explicit knowledge.
- test results measured for the manufactured products are used to evaluate the preferably coded products and, for example, to sort them according to a predetermined objective function and to select at least one product.
- this target function can be any combination of desired properties for the target compound sought and the sorting criterion can be derived from the extent to which the individual products fulfill this target function.
- the products are preferably evaluated according to their concentration dependence.
- the products can either be sorted in order of priority or divided into different evaluation categories.
- the target function can be any function that is constructed from the combination of the desired properties in the test systems used for the target connection sought. It is the evaluation criterion for sorting or categorizing the genomes according to how the individual corresponding products fulfill this objective function.
- concentration dependency of the test results has been determined and these are included in the target function, ie these properties are included in this target function in different and concentration-dependent weighting.
- the target function is particularly preferably a linear combination or a polynomial of these properties with “fuzzy” logic weightings, it being particularly preferred that the “fuzzy” logic weightings of individual properties may depend on the extent of the fulfillment of other properties and the number of cycles already completed.
- Such an objective function can thus take the form of a program according to the invention which evaluates a genome differently depending on different properties and conditions with logical and conditional links of different evaluation functions.
- such genomes can be given a high rating which, e.g. have a high oral bioavailability, or have several of these desirable properties after several cycles.
- compounds of the invention which have some desirable properties but also have properties which have been identified as undesirable, such as e.g. a measured logD value for the lipophilicity of over 5, received a negative evaluation, the desirable properties no longer being considered.
- step 5 the starting materials are determined which have led to the product (s) evaluated and selected in step 4.
- a sixth process step e.g. selected a new set of starting materials using an algorithm. Furthermore, a list is created of new experiments to be carried out, and the starting materials are combined in appropriately selected multicomponent combinations and brought to reaction, although an experiment that has already been carried out is preferably not repeatedly proposed.
- a variant or modification of at least one, preferably two of the starting materials determined in process step (5) is provided in the sense that at least one substituent is exchanged in this starting material and / or at least one (additional) substituent is introduced and / or an existing substituent is replaced by an H atom.
- more than one starting material and / or more than one reaction parameter such as the concentration of a starting material or the reaction temperature etc. are varied per cycle.
- the genomes of the previous cycle which are rated as the best are preferably used for the generation of the new genomes.
- a combinatorial optimization method such as a genetic algorithm or a pattern recognition method, such as, for example, a neural network or a combination of a genetic algorithm and a neural network, is used, wherein preferably a genetic algorithm or a pattern recognition method, such as, for example, a neural network or a combination of a genetic one Algorithm with a neural network implicitly or explicitly corrects the occurrence of desired properties with the components of the product genome of the previous generation.
- Those components of the genomes of the products tested which are more likely to correlate explicitly or implicitly with the desired properties are preferably used for the generation of the new genomes with a higher probability, preference being given to those genomes whose products have not received a good rating not for the generation new genomes are used, and preferably and randomly, individual components of the new genomes are selected from the number of possible codings by a random generator.
- Individual components of the new genomes are preferably and randomly removed or added from the genome by a random generator, the assignment of the probability of a random selection of such a building block preferably being dependent on the type of this building block, the genomes being particularly preferably randomly divided into one or more groups, so-called populations are classified.
- the genomes of a group are particularly preferably used only for the generation of new genomes of a new group of genomes and thus each of these populations will generate a new population, preferably after any number of cycles all populations of genomes into a new number of populations with the same number or a changed number of genomes.
- This reorganization is particularly preferably carried out if a product has particularly desirable properties in a population.
- the different coding of the starting materials, the reaction conditions, modifications, work-ups or preparatory steps are included as components of the genomes. defined for testing as well as the reaction vessels.
- this process step represents a transfer of the natural evolution of biopolymers such as DNA, RNA or peptides to the chemistry of the multicomponent reactions in conjunction with the properties of the chemical compounds produced by them.
- this step enables a significantly increased number of reaction options. Since any blocks of the genome can be deleted or added by the algorithm according to the invention, e.g. Multiple uses of a building block, such as a starting material, a catalyst, etc. possible.
- the peculiarity of the algorithm lies in the fact that, on the one hand, such genomes, ie combinations of starting materials, reaction conditions, modifications, work-ups or preparations for testing are preferred, the products of which also have the desired properties, and on the other hand those for the actual production of these unknown compounds even the best reaction conditions can be determined implicitly.
- the reaction leading to this product does not have to be known, it is optimized since, for example, a higher yield of the product resulting from this reaction is shown by an improvement in the desired properties.
- the starting materials and / or reactions / reaction conditions can optionally be varied individually or several or all together.
- the starting materials provided in the sixth process step are optionally reacted together with the other starting materials determined in process step (5):
- this starting material is preferably reacted with the other starting materials determined in process step (5) in addition to the starting material which was varied in process step (6).
- the starting materials Ei, E 2, E 3, E 4 and E 5 determined in step (5), and E 2 was in process step (6) to E 2 'varies, then in step (7) E 2' Ei, E 3 , E ⁇ and E 5 implemented.
- E 2' Ei, E 3 , E ⁇ and E 5 implemented.
- only one molecule is used in the reaction per starting material type, ie, for example, only one amine, one isocyanide, one carboxylic acid compound.
- process steps four to seven are repeated until a reaction product is found which fulfills the criteria of the target function, frequently up to 50, preferably up to 30, cycles being required to find such a product.
- the likelihood of finding such a product can be estimated after only 2 to 6 cycles, so that a path that is not very promising can be broken off at an early stage.
- the difference between the average degree of fulfillment of the target criteria by the products of a genome population from a cycle x and the average degree of fulfillment of the target criteria by the products of a genome population from a later cycle x + i is used for this estimate, where i is a completely natural one Number is.
- This difference can serve to select a new number of starting materials and to start the iterative process according to the invention again, especially if this difference is small.
- Process steps one to eight solve different problems in the discovery and optimization of new chemical compounds simultaneously in a novel and surprising manner.
- new multicomponent reactions are examined for their suitability for the production of new chemical compounds, preference being given to those multicomponent reactions which give products with desired properties.
- these products are varied according to the invention by the possible use of starting materials from the same class of substances which are necessary for these multicomponent reactions, and their properties are tested or optimized.
- these new multicomponent reactions are optimized themselves if the reaction conditions are components of the corresponding genomes.
- the chemical compounds contained in the reaction product which has shown the desired properties in the tests, are purified in a manner known per se, such as, for example, by chromatography or crystallization, and their structure using known processes such as mass spectroscopy or NMR spectroscopy certainly.
- the new process is described by way of example for the discovery and production of a very large variety of unnatural antibiotic, immunosuppressive, anti-neoplastic or antihelmintic polyketoid compounds with desired properties in order to clarify the advantages over existing processes.
- Polyketides are a structurally highly diverse family of natural products that are built up in nature through a common biosynthetic pathway. An exceptionally large number of substances with interesting biological activities were found in the polyketide family. For example, many representatives of the polyketides are cancer drugs, antibiotics, antihelmintics, immunosuppresives or the like. Prominent, commercially available examples are the tetracycline antibiotics, FK 506 and rapamycin, adriamycin and epothilone, or monensin (Fig. 1).
- Figure 1 Different structures of polyketides.
- Polyketides are formed by almost all classes of organisms, but primarily by mycelium-forming bacteria of the Actinomyces class.
- polyketides are synthesized using the so-called polyketide route. Putative polyketides are assumed to be the intermediate stage of biosynthesis (Fig. 2).
- Figure 2 A polyketide precursor that leads to different products depending on the cyclization mode.
- Polyketide synthases are multifunctional enzyme complexes that are related to fatty acid synthases.
- the structural diversity of the polyketides is due to the repetitive structure via decarboxylative claise condensation between different thioesters (mostly acetyl, propionyl, butyryl, malonyl, methylmalonyl) to polyketides and their modifications such as e.g. Reduction to alcohols, dehydration etc. occur.
- Each product of the polyketide synthesis pathway is created by a characteristic number of cycles, whereby at the end of the synthesis it is often cleaved from the PKS, often with cyclization.
- the first type I class is capable of complex macrolides such as To synthesize erythromycm.
- the second type II class is able to synthesize aromatic products.
- the new process is described by way of example for the production of a very large variety of unnatural antibiotic, immunosuppressive, antineoplastic or antihelmintic polyketides.
- Example 1 Preparation of a substance library of different multicomponent reactions with an antibacterial effect.
- 10 starting materials 1-10 (see Fig. 3) with different functional groups are selected: benzaldehyde 1, aniline 2, 3-phenyl-3-keto-propionic acid ethyl ester 3, 2,4-diketovaleric acid ethyl ester 4, 3- Keto-glutaric acid dirthylester 5, 2-keto-propionaldehyde 6, 3-methyl-2, 4-d ⁇ keto-pentane 7, 3, 5-d ⁇ keto-5-phenyl-valenoic acid 8, 2,4-diketo-phenyl-butyric acid 9 and Diphenylmethanisonit ⁇ l 10th
- Figure 3 The selected starting materials for a combinatorial library of 1023 different multicomponent reactions.
- the 10 starting materials were presented as 0.05M ethanol solutions for the combination of the individual reactions.
- the 1013 different combinations were carried out under four different reaction conditions (Set A, B, C, D).
- For each of the 4 * 1013 different reaction batches 20 ⁇ l of the corresponding educt solution were dispensed.
- the reaction set A from 1013 parallel batches was carried out without further additions.
- For reaction set B 10 ⁇ l of a 0.2M solution of p-toluenesulfonic acid in EtOH were additionally added.
- reaction set C an additional 10 ⁇ l of a 0.2M solution of triethylamm m EtOH was added.
- test germs were grown overnight in CASO broth (bacteria) at 35 ° C or Sabourad broth (yeast) at 22 ° C.
- the germ suspension was removed, the pellet resuspended in fresh medium and incubated for a further 2 hours.
- the pellet was then resuspended in 0.9% NaCl solution and the cell number was adjusted to about 10 8 CFU / ml (bacteria) or 10 7 CFU / ml (yeast) using the standard curves.
- the suspensions thus obtained were then diluted to about 10 6 CFU / ml in CASO broth (bacteria) or Sabourad broth. 15 ⁇ l of the solution of the reaction products was inoculated with 100 ⁇ l of these germ solutions. Immediately after the inoculation, as well as 7 and 22 hours of incubation, the plates were measured in a plate reader (Bio-tek EL 311 autoreader) at 550 nm.
- reaction sets A, B, C and D are compared in an analogous manner and the best reaction variants are taken into account in the next cycle of the process.
- the method consists of (1) creating an algorithmic library of different multicomponent reactions, starting from a library of suitable and diverse types of chemical starting materials, (2) biological testing of this library, (3) identifying suitable multicomponent reactions from this space of possible reactions , (4) selection of a large number of chemical starting materials of such types which are required for the identified and suitable multicomponent reactions, (5) finding optimal combinations from the chemical space constructed with them of these suitable multicomponent reactions by (6) algorithmic production and biological Testing compounds from this library.
- the process is illustrated using the example of finding new antibiotic table active polyketoid-like compounds exemplified.
- Table 1 The inhibitory activity of reaction set A of the 1013 different reactions from starting materials 1-10 against Pseudomonas aeruginosa.
- Table 2 The inhibitory activity of reaction set A of the 1013 different reactions from starting materials 1-10 against Staphylococcus aureus.
- Table 3 Sequence of the inhibitory activity of the best educt combinations of reaction set A according to a cycle of the process according to the invention against Pseudomonas aeruginosa.
- Table 4 Sequence of the inhibitory activity of the best educt combinations of reaction set A according to a cycle of the process according to the invention against Staphylococcus aureus.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU25429/00A AU2542900A (en) | 1999-01-21 | 2000-01-21 | Method for the combinatorial search for reactions for producing useful products |
AT00903606T ATE252527T1 (en) | 1999-01-21 | 2000-01-21 | METHOD FOR FINDING COMBINATORY REACTIONS FOR PRODUCING USEFUL PRODUCTS |
DE50004149T DE50004149D1 (en) | 1999-01-21 | 2000-01-21 | METHOD FOR COMBINATIONAL REACTION FINDING FOR THE PRODUCTION OF USEFUL PRODUCTS |
EP00903606A EP1144345B1 (en) | 1999-01-21 | 2000-01-21 | Method for the combinatorial search for reactions for producing useful products |
CA002360831A CA2360831A1 (en) | 1999-01-21 | 2000-01-21 | Method for the combinatorial search for reactions for producing useful products |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19902378.6 | 1999-01-21 | ||
DE19902378A DE19902378A1 (en) | 1999-01-21 | 1999-01-21 | Process for the discovery and production of biologically active chemical compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000043333A2 true WO2000043333A2 (en) | 2000-07-27 |
WO2000043333A3 WO2000043333A3 (en) | 2001-05-10 |
Family
ID=7895007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/000462 WO2000043333A2 (en) | 1999-01-21 | 2000-01-21 | Method for the combinatorial search for reactions for producing useful products |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1144345B1 (en) |
AT (1) | ATE252527T1 (en) |
AU (1) | AU2542900A (en) |
CA (1) | CA2360831A1 (en) |
DE (2) | DE19902378A1 (en) |
WO (1) | WO2000043333A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111429976A (en) * | 2020-03-24 | 2020-07-17 | 上海交通大学 | Optimized screening system and method for reaction flux for directionally removing impurities in molten metal |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994024314A1 (en) * | 1993-04-19 | 1994-10-27 | Kauffman Stuart A | Random chemistry for the generation of new compounds |
US5463564A (en) * | 1994-09-16 | 1995-10-31 | 3-Dimensional Pharmaceuticals, Inc. | System and method of automatically generating chemical compounds with desired properties |
-
1999
- 1999-01-21 DE DE19902378A patent/DE19902378A1/en not_active Withdrawn
-
2000
- 2000-01-21 CA CA002360831A patent/CA2360831A1/en not_active Abandoned
- 2000-01-21 EP EP00903606A patent/EP1144345B1/en not_active Expired - Lifetime
- 2000-01-21 WO PCT/EP2000/000462 patent/WO2000043333A2/en active IP Right Grant
- 2000-01-21 AT AT00903606T patent/ATE252527T1/en not_active IP Right Cessation
- 2000-01-21 DE DE50004149T patent/DE50004149D1/en not_active Expired - Lifetime
- 2000-01-21 AU AU25429/00A patent/AU2542900A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994024314A1 (en) * | 1993-04-19 | 1994-10-27 | Kauffman Stuart A | Random chemistry for the generation of new compounds |
US5463564A (en) * | 1994-09-16 | 1995-10-31 | 3-Dimensional Pharmaceuticals, Inc. | System and method of automatically generating chemical compounds with desired properties |
Non-Patent Citations (6)
Title |
---|
D\MLING A.: "Isocyanide based multi component reactions in combinatorial chemistry" COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, Bd. 1, 1998, Seiten 1-22, XP000960970 * |
FAUCHERE J -L ET AL: "Combinatorial chemistry for the generation of molecular diversity and the discovery of bioactive leads" CHEMOMETRICS AND INTELLIGEMT LABORATORY SYSTEMS,NL,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, Bd. 43, Nr. 1-2, 28. September 1998 (1998-09-28), Seiten 43-68, XP004146894 ISSN: 0169-7439 * |
KHOSLA C. & ZAWADA J.X.: "Generation of polyketide libraries via combinatorial biosynthesis" TIBTECH, Bd. 14, 1996, Seiten 335-341, XP002153819 * |
UGI I. ET AL.: "Molecular libraries in liquid phase via Ugi-MCR" RESEARCH OF CHEMICAL INTERMEDIATES, Bd. 22, 1996, Seiten 625-644, XP000961119 * |
WARR W A: "COMBINATORIAL CHEMISTRY AND MOLECULAR DIVERSITY. AN OVERVIEW" JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES,US,AMERICAN CHEMICAL SOCIETY, COLOMBUS,OHIO, Bd. 37, Nr. 1, 1997, Seiten 134-140, XP000765620 ISSN: 0095-2338 * |
WEBER L. ET AL.: "Optimization of the biological activity of combinatorial compound libraries by a genetic algorithm" ANGEWANDTE CHEMIE INT. ED., Bd. 34, Nr. 20, 1995, Seiten 2280-2282, XP002153818 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111429976A (en) * | 2020-03-24 | 2020-07-17 | 上海交通大学 | Optimized screening system and method for reaction flux for directionally removing impurities in molten metal |
CN111429976B (en) * | 2020-03-24 | 2023-04-18 | 上海交通大学 | Optimized screening system and method for reaction flux for directionally removing impurities in molten metal |
Also Published As
Publication number | Publication date |
---|---|
EP1144345A2 (en) | 2001-10-17 |
DE19902378A1 (en) | 2000-08-03 |
WO2000043333A3 (en) | 2001-05-10 |
CA2360831A1 (en) | 2000-07-27 |
DE50004149D1 (en) | 2003-11-27 |
ATE252527T1 (en) | 2003-11-15 |
AU2542900A (en) | 2000-08-07 |
EP1144345B1 (en) | 2003-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000049142A1 (en) | Method for producing polymers | |
DE102009033368A1 (en) | Mass spectrometric sepsis diagnosis | |
Bitzer et al. | Accelerated dereplication of natural products, supported by reference libraries | |
EP1144345B1 (en) | Method for the combinatorial search for reactions for producing useful products | |
DE19619373A1 (en) | New substance library and the resulting supramolecular complexes | |
DE10128510A1 (en) | New nucleic acid array useful for monitoring mRNA expression of Corynebacterium glutamicum during fermentation, comprising nucleic acid from Corynebacterium glutamicum | |
EP1330655A1 (en) | Method for analyzing proteins | |
DE19925402C2 (en) | Screening of target-ligand interactions | |
DE60023269T2 (en) | Development of a screening method for a physiologically active pyrrole-imidazole derivative | |
DE102011117582B4 (en) | Reactants for charge transfer reactions in mass spectrometers | |
EP1745063B1 (en) | Method for producing chemical microarrays | |
DE69909312T2 (en) | METHODS FOR IDENTIFYING "HOT SPOT" REMAINING BINDING PROTEINS AND SMALL COMPOUNDS THAT BIND TO THESE | |
EP1260592A1 (en) | Biochip | |
DE60225031T2 (en) | UML oligomers, their compositions and processes for their preparation | |
DE69737327T2 (en) | METHOD FOR IDENTIFYING ESSENTIAL GENES FOR THE GROWTH OF AN ORGANISM | |
DE102011050363A1 (en) | Stepwise synthesizable capture compounds and methods for protein isolation from complex mixtures | |
Wilson et al. | The identification and characterization of hydrazinyl urea-based antibacterial agents through combinatorial chemistry | |
EP0655135B1 (en) | Random generation and bio-specific selection of chemical compounds | |
WO2004010347A2 (en) | Method and installation for solving problems of adaptive chemistry | |
EP1412079B1 (en) | Method and device for finding substance mixtures for substance libraries | |
DE19713556A1 (en) | Identification of eukaryotic, prokaryotic and viral species e.g. E. coli, B. subtilis and H. influenzae | |
WO2005028671A2 (en) | Method for determining hair cycle markers | |
DE19743176A1 (en) | Process for the separation of complex substance mixtures by means of solid phase extraction for use in the search for active substances and for analytical purposes | |
EP0299350A2 (en) | Anthracyclin derivatives with cytostatic activity | |
WO2004029286A2 (en) | Method for identifying the enzyme activities of any protein extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref document number: 2360831 Country of ref document: CA Ref country code: CA Ref document number: 2360831 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000903606 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000903606 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09889807 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000903606 Country of ref document: EP |